Stock DSNKY DAIICHI SANKYO COMPANY, LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Daiichi Sankyo Company, Limited OTC Markets

Equities

DSNKY

US23381D1028

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 20:59:13 31/05/2024 BST 		5-day change 1st Jan Change
35.38 USD +2.61% Intraday chart for Daiichi Sankyo Company, Limited +2.17% +29.36%
05-28 RevolKa Signs Master Service Agreement with Daiichi Sankyo CI
05-27 AstraZeneca, Daiichi Sankyo's Experimental Lung Cancer Drug Shows Improvement in Patients DJ

Valuation

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 3,304,011 4,816,951 6,179,276 5,136,821 9,244,546 10,692,720 - -
Enterprise Value (EV) 1 2,785,091 4,159,929 5,538,193 4,456,437 8,995,480 8,614,202 10,008,901 10,017,978
P/E ratio 35.4 x 37.3 x 82.3 x 76.7 x 84.7 x 45.6 x 54.2 x 41.5 x
Yield 1.37% 0.94% 0.84% 1.01% 0.62% 1.05% 1.08% 1.23%
Capitalization / Revenue 3.55 x 4.91 x 6.42 x 4.92 x 7.23 x 5.72 x 6.03 x 5.13 x
EV / Revenue 3 x 4.24 x 5.75 x 4.26 x 7.04 x 5.38 x 5.65 x 4.81 x
EV / EBITDA 21.4 x 21.7 x 45.7 x 33.9 x 47.8 x 31.8 x 33.2 x 26.2 x
EV / FCF 49.8 x 36.2 x 36.2 x 58.3 x -62.8 x 27.2 x 92.2 x 70.7 x
FCF Yield 2.01% 2.76% 2.76% 1.72% -1.59% 3.68% 1.08% 1.41%
Price to Book 2.64 x 3.69 x 4.86 x 3.8 x 6.39 x 5.43 x 6.48 x 6.07 x
Nbr of stocks (in thousands) 1,943,536 1,943,887 1,916,055 1,916,724 1,917,160 1,916,945 - -
Reference price 2 1,700 2,478 3,225 2,680 4,822 5,578 5,578 5,578
Announcement Date 25/04/19 27/04/20 27/04/21 27/04/22 27/04/23 25/04/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 929,717 981,793 962,516 1,044,900 1,278,478 1,601,700 1,772,496 2,082,583
EBITDA 1 129,874 191,411 121,177 131,270 188,369 271,234 301,849 382,355
EBIT 1 83,705 138,800 63,795 73,000 120,580 211,600 235,697 315,570
Operating Margin 9% 14.14% 6.63% 6.99% 9.43% 13.21% 13.3% 15.15%
Earnings before Tax (EBT) 1 85,831 141,164 74,124 73,500 126,854 237,200 246,730 329,164
Net income 1 93,409 129,074 75,958 67,000 109,188 200,700 196,670 256,556
Net margin 10.05% 13.15% 7.89% 6.41% 8.54% 12.53% 11.1% 12.32%
EPS 2 48.07 66.40 39.17 34.94 56.96 104.7 102.9 134.4
Free Cash Flow 1 55,925 114,928 152,961 76,490 -143,268 316,622 108,562 141,679
FCF margin 6.02% 11.71% 15.89% 7.32% -11.21% 19.77% 6.12% 6.8%
FCF Conversion (EBITDA) 43.06% 60.04% 126.23% 58.27% - 116.73% 35.97% 37.05%
FCF Conversion (Net income) 59.87% 89.04% 201.38% 114.16% - 157.76% 55.2% 55.22%
Dividend per Share 2 23.33 23.33 27.00 27.00 30.00 50.00 60.00 68.85
Announcement Date 25/04/19 27/04/20 27/04/21 27/04/22 27/04/23 25/04/24 - -
1JPY in Million2JPY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: March 2020 S1 2020 S2 2021 S1 2022 Q2 2022 S1 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 S1 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2 2025 S1 2025 Q3 2025 Q4 2025 S2 2026 S1 2026 S2
Net sales 1 479,573 502,220 480,168 265,896 529,965 281,002 233,933 - 280,317 327,480 607,797 340,479 330,202 350,835 375,465 726,300 446,925 428,431 - 401,794 425,100 781,368 477,625 471,975 - - -
EBITDA 1 - - - - - - - - - - - - - - - - 114,454 33,427 - 110,400 56,200 - 83,300 47,200 - - -
EBIT 1 86,163 52,637 58,465 38,973 84,742 39,030 -50,772 - 34,382 61,198 95,580 31,551 -6,551 44,032 51,068 95,100 99,488 17,049 - 55,701 52,240 79,410 69,384 44,898 - - -
Operating Margin 17.97% 10.48% 12.18% 14.66% 15.99% 13.89% -21.7% - 12.27% 18.69% 15.73% 9.27% -1.98% 12.55% 13.6% 13.09% 22.26% 3.98% - 13.86% 12.29% 10.16% 14.53% 9.51% - - -
Earnings before Tax (EBT) 1 87,040 54,124 66,986 38,893 85,955 39,931 -52,386 - 29,415 61,850 91,265 36,185 -596 52,133 49,967 102,100 97,749 37,354 - 58,598 49,400 85,110 68,650 49,150 - - -
Net income 1 64,426 64,648 51,667 27,245 62,465 31,853 -27,318 - 18,851 39,458 58,309 28,391 22,488 57,013 39,987 97,000 66,558 37,136 - 49,248 45,539 68,404 57,160 41,633 - - -
Net margin 13.43% 12.87% 10.76% 10.25% 11.79% 11.34% -11.68% - 6.72% 12.05% 9.59% 8.34% 6.81% 16.25% 10.65% 13.36% 14.89% 8.67% - 12.26% 10.71% 8.75% 11.97% 8.82% - - -
EPS 2 33.15 - 26.57 14.21 32.59 16.62 -10.07 - 9.840 20.58 30.42 14.81 11.73 29.74 20.85 50.59 34.72 19.38 - 19.25 24.81 22.60 30.89 30.57 - - -
Dividend per Share 2 11.67 11.67 13.50 - 13.50 - - 13.50 - - 15.00 - - - 20.00 20.00 - 30.00 17.00 - 30.00 20.00 - 30.00 20.00 25.00 25.00
Announcement Date 31/10/19 27/04/20 30/10/20 29/10/21 29/10/21 31/01/22 27/04/22 27/04/22 29/07/22 31/10/22 31/10/22 31/01/23 27/04/23 31/07/23 31/10/23 31/10/23 31/01/24 25/04/24 - - - - - - - - -
1JPY in Million2JPY
Estimates

Balance Sheet Analysis

Fiscal Period: March 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 518,920 657,022 641,083 680,384 249,066 545,467 683,819 674,742
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 55,925 114,928 152,961 76,490 -143,268 316,622 108,562 141,679
ROE (net income / shareholders' equity) 7.8% 10.1% 5.9% 5.1% 7.8% 12.8% 11.8% 13.6%
ROA (Net income/ Total Assets) 4.31% 6.7% 3.54% 3.41% 5.36% 7.95% 6.41% 8.16%
Assets 1 2,168,857 1,926,478 2,147,241 1,962,438 2,035,768 2,525,319 3,066,951 3,143,687
Book Value Per Share 2 643.0 672.0 664.0 705.0 754.0 880.0 860.0 918.0
Cash Flow per Share 2 71.80 101.0 68.80 65.30 92.30 136.0 132.0 143.0
Capex 1 36,108 31,936 31,245 62,736 71,539 88,321 85,740 106,434
Capex / Sales 3.88% 3.25% 3.25% 6% 5.6% 5.51% 4.84% 5.11%
Announcement Date 25/04/19 27/04/20 27/04/21 27/04/22 27/04/23 25/04/24 - -
1JPY in Million2JPY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Daiichi Sankyo Company, Limited

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
5,578 JPY
Average target price
5,977 JPY
Spread / Average Target
+7.15%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
NOVARTIS AG Stock Novartis AG
+9.78% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 4568 Stock
  4. DSNKY Stock
  5. Financials Daiichi Sankyo Company, Limited